Skip to main content
main-content

Oncology

Latest articles

14-06-2019 | Oncology | News | Article

TAK-788 shows activity against NSCLC with EGFR exon 20 insertions

The EGFR and HER2 inhibitor TAK-788 has antitumor activity against non-small-cell lung cancer with EGFR exon 20 insertions, according to phase I/II findings reported at the 2019 ASCO Annual Meeting.

14-06-2019 | Oncology | News | Article

ENZAMET supports enzalutamide use in men with metastatic CSPC

Men with metastatic castration-sensitive prostate cancer derive a significant overall survival benefit from the addition of enzalutamide to standard testosterone suppression, show phase III trial results.

13-06-2019 | Oncology | News | Article

BLU-667 active against RET fusion-positive advanced NSCLC

Phase I data indicate that the selective RET inhibitor BLU-667 elicits durable responses and is well tolerated by individuals with advanced non-small-cell lung cancer harboring a RET fusion.

11-06-2019 | Oncology | News | Article

RELAY: Ramucirumab–erlotinib a potential first-line option for EGFR-mutated NSCLC

Combining erlotinib with ramucirumab significantly improves the progression-free survival of untreated patients with advanced EGFR mutation-positive non-small-cell lung cancer, suggest phase III results presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA.

09-06-2019 | Oncology | Main feed | News

KEYNOTE-426 subgroup analyses confirm pembrolizumab–axitinib efficacy

Research presented at the 2019 ASCO Annual Meeting in Chicago, Illinois, USA, adds support for use of pembrolizumab plus axitinib  as a first-line treatment for patients with metastatic renal cell carcinoma.

07-06-2019 | Oncology | News | Article

Prolonged survival possible with pembrolizumab in advanced NSCLC

Updated results from the phase Ib KEYNOTE-001 trial suggest that some individuals with advanced non-small-cell lung cancer can achieve long-term survival with pembrolizumab monotherapy.

Image Credits